• Genfit flagged new preclinical ACLF data on nitazoxanide and SRT-015 for presentation at EASL Congress 2026.
• The studies point to potential benefits on organ dysfunction and immune balance in disease models, supporting the company’s ACLF development strategy.
• No clinical trial readouts were disclosed; real-world analyses will be presented on care gaps, infections, hepatic encephalopathy treatment, coding uptake.
• Genfit does not expect to present GNS561 cholangiocarcinoma data at EASL while Phase 1 dose escalation continues.
• Ipsen will present new elafibranor datasets in PBC at EASL, reinforcing progress in the partnered program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605251200OMX_____CNEWS_EN_GNW1001183612_en) on May 25, 2026, and is solely responsible for the information contained therein.